x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Prova Education

Prova Education designs educational programs that address a broad spectrum of gaps in awareness, attitudes, skills, and competencies related to guideline-based care and evolving disease management options. Its mission is to serve as an innovative and relevant resource for clinical content that promotes change in practice and patient outcomes.

science & medicine medicine

All Episodes

00:00:00

Keeping Pace in Lung Cancer - HER2: Unveiling New...

Prova Education ·

2023/11/15

Guest: Jacob Sands, MD Host: Charu Aggarwal, MD, MPH We now have an FDA-approved targeted therapy to treat HER2-mutated NSCLC. Drs. Aggarwal and Sands discuss the most current clinical data, including management of adverse events.

en

00:00:00

What’s New About Gout? Nephrology Perspective

Prova Education ·

2023/10/24

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout

en

00:00:00

Treat or Refer: Who Is Responsible for Managing Gout?

Prova Education ·

2023/10/24

Host: John K. Botson, MD, RPh Guest: Abdul Abdellatif, MD, FASN Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory

en

00:00:00

What’s New About Gout? Rheumatology Perspective

Prova Education ·

2023/10/24

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and

en

00:00:00

Can You Manage Patients With Uncontrolled Gout More...

Prova Education ·

2023/10/24

Host: Abdul Abdellatif, MD, FASN Guest: John K. Botson, MD, RPh Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory

en

00:00:00

Center of the Target: Which Patients Are Most Likely...

Prova Education ·

2023/10/24

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout

en

00:00:00

Gout Beyond the Joints: What’s the Hidden Danger?

Prova Education ·

2023/10/24

Host: Richard Johnson, MD Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of

en

00:00:00

What Are the Emerging Therapies for Managing Gout?

Prova Education ·

2023/10/24

Host: Richard Johnson, MD Guest: John K. Botson, MD, RPh Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and

en

00:00:00

Is Managing Gout in the Nephrology Clinic a Challenge?

Prova Education ·

2023/10/24

Host: Richard Johnson, MD Guest: Abdul Abdellatif, MD, FASN Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout

en

00:00:00

Is Gout Hiding in the Nephrology Clinic?

Prova Education ·

2023/10/24

Host: Abdul Abdellatif, MD, FASN Guest: Richard Johnson, MD Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout

en

00:00:00

Should We Look for Gout in the Cardiology Clinic?

Prova Education ·

2023/10/24

Host: Richard Johnson, MD Guest: Brittany Weber, MD, PhD Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and

en

00:00:00

A Look at the Numbers: Cost of Durable Treatments in...

Prova Education ·

2023/09/15

Host: Jayanth Sridhar, MD Host: Sabin Dang, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in

en

00:00:00

Reconsidering the Algorithm: DME

Prova Education ·

2023/09/15

Host: Christina Y. Weng, MD, MBA Host: Durga Borkar, MD, MMCi The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data

en

00:00:00

Reconsidering the Algorithm: nAMD

Prova Education ·

2023/09/15

Host: Sabin Dang, MD Host: Jayanth Sridhar, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in

en

00:00:00

Clinical Evidence for Durable Treatment of nAMD

Prova Education ·

2023/09/15

Host: Sabin Dang, MD Host: Jayanth Sridhar, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in

en

00:00:00

A Closer Look at Real-World Strategies for...

Prova Education ·

2023/09/15

Host: Durga Borkar, MD, MMCi Host: Christina Y. Weng, MD, MBA The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data

en

00:00:00

Clinical Evidence for Durable Treatment of DME

Prova Education ·

2023/09/15

Host: Christina Y. Weng, MD, MBA Host: Durga Borkar, MD, MMCi The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data

en

00:00:00

Reconsidering the Algorithm: Treatment-Resistant DME

Prova Education ·

2023/09/15

Host: Durga Borkar, MD, MMCi Host: Christina Y. Weng, MD, MBA The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data

en

00:00:00

Real-World Treatment of Retinal Disease

Prova Education ·

2023/09/15

Host: Jayanth Sridhar, MD Host: Sabin Dang, MD The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in

en

00:00:00

Real-World Outcomes with Durable Treatments for...

Prova Education ·

2023/09/15

Host: Christina Y. Weng, MD, MBA Host: Durga Borkar, MD, MMCi The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data

en

134 results

Similar Podcasts

科学史评话最新专辑

科学史评话

Hablando con Científicos - Cienciaes.com

cienciaes.com

天方烨谈

基因频道

The Permaculture Podcast

Scott Mann

汪诘：科学有故事（主打）

科学有故事